M3 : Notice of Amendment to Dividend Payout Forecast
February 25, 2021 at 01:04 am EST
Share
FOR IMMEDIATE RELEASE: 2021/2/25
Listed Name:
M3, Inc.
(TSE Section 1 Ticker Code: 2413)
(https://corporate.m3.com/en)
Headquarters:
1-11-44 Akasaka, Minato-ku, Tokyo
Representative:
Itaru Tanimura, Representative Director
Contact:
Eiji Tsuchiya, Director
Phone'
03-6229-8900 (main line)
Notice of Amendment to Dividend Payout Forecast
M3, Inc. announces that its Board of Directors today resolved to amend the forecast of dividends as detailed below, for the fiscal year ended March 31, 2021.
1. Reason for Amendment of Forecast
At M3, Inc., our basic policy is to retain and reinvest profits to further strengthen our operating foundations and drive business development, while comprehensively considering capital needs and condition of cash-flows when determining dividend payouts to our shareholders.
For the current fiscal year, we have determined that we are in a position to redistribute profits in the form of ordinary dividend payout of 12 yen.
Going forward, our basic policy to reinvestment for further growth remains unchanged.
2. Breakdown of Dividend Amendment
Annual Dividends per Share (yen)
As of
End of First Half
Year-End
Total
Previous Forecast (Announced on January 29, 2021)
To be determined
To be determined
Current Amended Forecast
12
12
Total Amount of Dividends for the Fiscal Year ending March 31, 2021
0
FY2019 Actual (ended March 31, 2020)
0
8.5
8.5
Disclaimer:
This document is a translation of the original Japanese version. The original Japanese version was prepared and disclosed by the Company in accordance with Japanese disclosure format. This document does not contain or constitute any guarantee and the Company will not compensate for any losses or damages arising from interpretations or actions taken based on this document. In the case of any discrepancies between the Japanese original and this document, the Japanese original is assumed to be correct.
Attachments
Original document
Permalink
Disclaimer
M3 Inc. published this content on 25 February 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 February 2021 06:03:16 UTC.
M3, Inc. specializes in the provision of online services dedicated to the health field. Net sales (before intra-group eliminations) break down by activity as follows:
- medical marketing support services (40.3%): services enabling doctors and health professionals to search for medical resources, use the latest medical news, exchange opinions, learn about medical products and services and career development, etc. via m3.com., MR-kun, MDLinx and MEDI: GATE;
- support services to medical institutions (16.5%):
- clinical trial related services (10.7%): clinical trial support and clinical trial operations management services;
- human resources services (6.6%);
- other (1.6%): including marketing assistance and surveys of affiliated medical companies via specialized sites.
The balance of sales (24.3%) concerns international activities.